secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001835268-26-000016
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma: DMC Recommends Continue Phase 2 Asthma/COPD Trials; Topline Data Mid-2026
--------------------------------------------------------------------------------

- DMC reviewed pre-specified interim efficacy of rademikibart (anti-IL-4Rα) in Phase 2 Seabreeze STAT trials; no sample size change.
- No treatment-related serious adverse events, no severe AEs, and no discontinuations due to AEs in either study.
- Topline data from both asthma and COPD studies expected in mid-2026; company plans FDA meeting for Phase 3.
- CEO Barry Quart: 'Rademikibart has potential to deliver differentiated efficacy and safety in acute exacerbations.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/0001835268-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/cntb-20260423.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer